Bolivia (Plurinational State of) vs China: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Bolivia (Plurinational State of)
0.1%
in 2024
China
0.1%
in 2024
Bolivia (Plurinational State of) rank
135th
China rank
135th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Bolivia (Plurinational State of)
- China
How they compare
Bolivia (Plurinational State of) currently reports 0.1% against 0.1% in China, a difference of 0.0%.
Across all 10 years both countries report, China has been ahead every year.
Bolivia (Plurinational State of) ranks 135th and China ranks 135th of 247 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bolivia (Plurinational State of) | China | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.2% | 0.2% | China |
| 2020s | 0.1% | 0.1% | 0.0% | China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Bolivia (Plurinational State of) or China?
- Bolivia (Plurinational State of), at 0.1% against 0.1% in China as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Bolivia (Plurinational State of) and China?
- 0.0%, with Bolivia (Plurinational State of) ahead.
- How many years of comparable data are there for Bolivia (Plurinational State of) and China?
- 10 years are reported by both, from 2015 to 2024.
- How do Bolivia (Plurinational State of) and China rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Bolivia (Plurinational State of) ranks 135th and China ranks 135th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.